argenx SE (ARGX) income statement
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$925.70−16.34 (-1.73%)
Close on Nov 20, 2026Market cap –P/E 47.3Yield –
argenx SE financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap –P/E 47.3Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||||||
| Gross margin | – | – | -231.6% | -193.5% | – | – | – | – | – | – | – | – |
| Operating margin | – | – | -1,196.2% | -7,184.7% | -70.1% | -1,158.1% | -253.5% | -381.0% | – | – | – | – |
| Pre-tax margin | – | – | -856.9% | -7,274.2% | -80.4% | -1,467.8% | -224.2% | – | – | – | – | – |
| Net profit margin | – | – | -830.4% | -7,077.5% | -82.1% | -1,475.3% | – | – | – | – | – | – |
| Free cash flow margin | – | – | -1,185.2% | -8,614.0% | -122.8% | -968.7% | 191.0% | – | – | – | – | – |
| Effective tax rate | -1.1% | -878.0% | – | – | – | – | – | – | – | – | – | – |
| Returns on capital | ||||||||||||
| Return on equity | 20.2% | 17.4% | -8.5% | -26.5% | -19.4% | -42.6% | – | – | – | – | – | – |
| Return on assets | 17.4% | 15.5% | -7.7% | -23.7% | -15.9% | -31.3% | – | – | – | – | – | – |
| Return on tangible assets | 18.0% | 16.0% | -7.9% | -25.2% | -17.1% | -34.2% | – | – | – | – | – | – |
| Return on capital employed | 16.3% | -0.45% | -12.2% | -26.8% | -15.5% | -28.2% | -13.9% | – | – | – | – | – |
| NOPAT | $1.05B | -$21.65M | -$335.79M | -$569.07M | -$275.51M | -$377.32M | -$157.12M | -$64.66M | – | – | – | – |
| Cash flow quality | ||||||||||||
| OCF / Sales | – | – | -1,182.9% | -8,605.7% | -122.0% | -966.1% | 193.3% | – | – | – | – | – |
| OCF / Net income | 0.53 | -0.10 | 1.42 | 1.22 | 1.49 | 0.65 | – | – | – | – | – | – |
| FCF / OCF | 99.1% | 102.2% | 100.2% | 100.1% | 100.6% | 100.3% | 98.8% | – | – | – | – | – |
| FCF / Net income | 0.53 | -0.10 | 1.43 | 1.22 | 1.50 | 0.66 | – | – | – | – | – | – |
| Unlevered free cash flow | $682.25M | -$82.60M | -$420.42M | -$860.56M | -$606.82M | -$393.24M | $149.83M | – | – | – | – | – |
| Levered free cash flow | $679.03M | -$84.55M | -$421.14M | -$863.64M | -$610.44M | -$399.53M | $149.83M | – | – | – | – | – |
| Efficiency | ||||||||||||
| Asset turnover | – | – | 0.01 | 0.00 | 0.19 | 0.02 | 0.05 | – | – | – | – | – |
| Fixed asset turnover | – | – | 1.83 | 0.63 | 36.26 | 3.97 | 8.55 | – | – | – | – | – |
| Receivables turnover | – | – | 0.09 | 0.06 | 22.00 | 2.14 | 2.48 | – | – | – | – | – |
| Days sales outstanding | – | – | 3,967.0 | 5,714.1 | 16.6 | 170.6 | 146.9 | – | – | – | – | – |
| Payables turnover | 0.47 | 0.43 | 0.33 | 0.10 | – | – | – | – | – | – | – | – |
| Days payables outstanding | 776.3 | 854.3 | 1,099.2 | 3,652.9 | – | – | – | – | – | – | – | – |
| Inventory turnover | 1.02 | 0.63 | 0.44 | 0.17 | – | – | – | – | – | – | – | – |
| Days inventory outstanding | 356.9 | 576.3 | 834.6 | 2,092.4 | – | – | – | – | – | – | – | – |
| Operating cycle | – | – | 4,801.7 | 7,806.5 | – | – | – | – | – | – | – | – |
| Cash conversion cycle | – | – | 3,702.5 | 4,153.6 | – | – | – | – | – | – | – | – |
| CapEx to revenue | – | – | 2.3% | 8.3% | 0.73% | 2.6% | 2.3% | – | – | – | – | – |
| CapEx to OCF | 0.90% | -2.2% | -0.19% | -0.10% | -0.60% | -0.27% | 1.2% | – | – | – | – | – |
| Liquidity | ||||||||||||
| Current ratio | 5.23 | 7.29 | 9.75 | 9.18 | 8.44 | 6.26 | 8.58 | – | – | – | – | – |
| Quick ratio | 4.87 | 6.68 | 9.01 | 8.42 | 8.08 | 6.19 | 8.58 | – | – | – | – | – |
| Cash ratio | 2.64 | 2.24 | 4.84 | 2.65 | 4.43 | 3.70 | 2.07 | – | – | – | – | – |
| Working capital | $5.58B | $4.21B | $3.70B | $2.47B | $2.24B | $1.73B | $1.36B | – | – | – | – | – |
| Net current asset value | $5.54B | $4.18B | $3.68B | $2.45B | $2.23B | $1.45B | $1.11B | – | – | – | – | – |
| Leverage | ||||||||||||
| Assets to equity | 1.19 | 1.13 | 1.11 | 1.11 | 1.12 | 1.36 | 1.36 | – | – | – | – | – |
| Intangibles to total assets | 3.1% | 2.9% | 2.8% | 5.6% | 6.0% | 7.3% | 2.8% | – | – | – | – | – |
| Interest coverage | ||||||||||||
| EBIT / Interest expense | 258.16 | -8.79 | -469.15 | -184.42 | -76.18 | -60.00 | – | – | – | – | – | – |
| Per share | ||||||||||||
| Revenue per share | – | – | 0.60 | 0.18 | 9.62 | 0.87 | 1.83 | 0.60 | – | – | – | – |
| EPS (basic) | 21.08 | 13.92 | -5.16 | -13.05 | -7.99 | -13.40 | -4.69 | – | – | – | – | – |
| EPS (diluted) | 19.57 | 12.78 | -5.16 | -13.05 | -7.99 | -13.40 | -4.69 | – | – | – | – | – |
| Book value per share | 118.34 | 90.49 | 69.22 | 50.79 | 49.05 | 35.19 | 27.60 | 17.14 | – | – | – | – |
| Tangible book value per share | 113.94 | 87.50 | 67.11 | 47.64 | 45.73 | 31.67 | 26.55 | 17.14 | – | – | – | – |
| Cash per share | 56.41 | 24.69 | 34.61 | 14.45 | 25.83 | 25.58 | 8.70 | 8.94 | – | – | – | – |
| Operating cash flow per share | 11.07 | -1.36 | -7.10 | -15.58 | -11.74 | -8.38 | 3.55 | – | – | – | – | – |
| Free cash flow per share | 10.97 | -1.39 | -7.11 | -15.59 | -11.81 | -8.40 | 3.50 | – | – | – | – | – |
| CapEx per share | 0.10 | 0.03 | 0.01 | 0.02 | 0.07 | 0.02 | 0.04 | – | – | – | – | – |
| Valuation at period end | ||||||||||||
| Market cap | $51.44B | $36.77B | $21.29B | $20.86B | $18.00B | $12.58B | $5.77B | $3.09B | $1.27B | – | – | – |
| Enterprise value | $49.35B | $35.34B | $20.18B | $19.49B | $16.42B | $12.20B | $5.45B | $3.09B | $1.27B | – | – | – |
| P/E | 39.8x | 44.1x | – | – | – | – | – | – | – | – | – | – |
| P/S | – | – | 599x | 2,080x | 36.2x | 305x | 73.6x | 144x | – | – | – | – |
| P/B | 7.0x | 6.7x | 5.2x | 7.4x | 7.1x | 7.5x | 4.9x | 5.0x | – | – | – | – |
| P/TBV | 7.3x | 6.9x | 5.4x | 7.9x | 7.6x | 8.3x | 5.1x | 5.0x | – | – | – | – |
| P/Gross profit | – | – | -259x | -1,075x | – | – | – | – | – | – | – | – |
| P/OCF | 75.1x | -444x | -50.6x | -24.2x | -29.7x | -31.6x | 38.1x | – | – | – | – | – |
| P/FCF | 75.8x | – | – | – | – | – | 38.5x | – | – | – | – | – |
| EV/Sales | – | – | 568x | 1,944x | 33.0x | 296x | 69.5x | 144x | – | – | – | – |
| EV/Gross profit | – | – | -245x | -1,004x | – | – | – | – | – | – | – | – |
| EV/EBIT | 46.8x | – | – | – | – | – | – | – | – | – | – | – |
| EV/OCF | 72.0x | -427x | -48.0x | -22.6x | -27.1x | -30.6x | 36.0x | – | – | – | – | – |
| EV/FCF | 72.7x | – | – | – | – | – | 36.4x | – | – | – | – | – |
| Earnings yield | 2.5% | 2.3% | -1.4% | -3.4% | -2.3% | -4.8% | – | – | – | – | – | – |
| FCF yield | 1.3% | -0.23% | -2.0% | -4.1% | -3.4% | -3.2% | 2.6% | – | – | – | – | – |
| Cost structure | ||||||||||||
| R&D to revenue | – | – | 2,418.9% | 6,616.5% | 116.7% | 899.3% | 281.4% | 389.2% | – | – | – | – |
| SG&A to revenue | – | – | 2,003.5% | 4,709.1% | – | – | – | – | – | – | – | – |
| Stock-based comp to revenue | – | – | 655.7% | 1,566.2% | 36.1% | 235.0% | 56.4% | – | – | – | – | – |
| Per employee | ||||||||||||
| Total employees | 1,863 | 1,599 | 1,148 | 843 | 650 | 336 | 230 | 250 | 90 | 90 | 90 | 90 |
| Revenue per employee | – | – | $30.95K | $11.89K | $765.04K | $122.75K | $341.14K | $85.93K | – | – | – | – |
| Gross profit per employee | – | – | -$71.69K | -$23.02K | – | – | – | – | – | – | – | – |
| Operating profit per employee | $565.65K | -$13.54K | -$370.25K | -$854.50K | -$536.53K | -$1.42M | -$864.75K | -$327.40K | – | – | – | – |
| Net income per employee | $693.52K | $520.98K | -$257.01K | -$841.75K | -$628.10K | -$1.81M | – | – | – | – | – | – |
| Free cash flow per employee | $364.48K | -$52.88K | -$366.85K | -$1.02M | -$939.13K | -$1.19M | $651.45K | – | – | – | – | – |
| Growth | ||||||||||||
| Revenue 1Y growth | – | – | 254.4% | -98.0% | 1,105.7% | -47.4% | 265.2% | – | – | – | – | – |
| Revenue 3Y CAGR | – | – | -4.8% | -49.6% | 185.0% | – | – | – | – | – | – | – |
| Revenue 5Y CAGR | – | – | 10.6% | – | – | – | – | – | – | – | – | – |
| Gross profit 1Y growth | – | – | -324.1% | – | – | – | – | – | – | – | – | – |
| EBIT 1Y growth | 4,966.6% | 94.9% | 41.0% | -106.6% | 27.0% | -140.1% | -143.0% | – | – | – | – | – |
| Net income 1Y growth | 55.1% | 382.3% | 58.4% | -73.8% | 32.9% | – | – | – | – | – | – | – |
| Diluted EPS 1Y growth | 53.1% | 347.7% | 60.5% | -63.3% | 40.4% | -185.7% | – | – | – | – | – | – |
| Operating cash flow 1Y growth | 928.1% | 80.3% | 51.3% | -42.2% | -52.3% | -362.8% | – | – | – | – | – | – |
| Free cash flow 1Y growth | 903.1% | 79.9% | 51.2% | -41.5% | -52.8% | -366.6% | – | – | – | – | – | – |
| CapEx 1Y growth | 242.3% | 121.8% | -3.0% | -76.9% | 239.2% | -40.5% | – | – | – | – | – | – |
| CapEx 3Y CAGR | 94.6% | -20.8% | -8.7% | -22.5% | – | – | – | – | – | – | – | – |
| CapEx 5Y CAGR | 42.0% | 0.06% | – | – | – | – | – | – | – | – | – | – |
| Total assets 1Y growth | 40.0% | 36.5% | 44.9% | 10.0% | 25.0% | 41.6% | – | – | – | – | – | – |
| Total assets 3Y CAGR | 40.4% | 29.6% | 25.8% | 24.9% | – | – | – | – | – | – | – | – |
| Total assets 5Y CAGR | 30.7% | 31.0% | – | – | – | – | – | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.